Search

Résumé:Des mesures fiables du fardeau de traitement sont requises étant donné le vieillissement de la population et l’augmentation de la multimorbidité et de la polypharmacie qui y est associée. Le fardeau de traitement correspond aux efforts fournis pour prendre soin de sa santé et aux impacts que cela peut avoir sur la vie de tous les jours. Cette étude avait pour but de traduire le Multimorbidity Treatment Burden Questionnaire (MTBQ) pour la population canadienne-française et d’évaluer sa fiabilité et sa validité. Le MTBQ a été traduit et testé à l’aide d’entretiens cognitifs, et la version française (MTBQ-F) a ensuite été administrée deux fois auprès de 105 participants. La fiabilité et la validité ont été évaluées par le biais du coefficient de corrélation intra-classe (CCI), de l’alpha de Cronbach et de corrélations de Spearman. Le score global médian au MTBQ-F était de 32,69 (écart interquartile [EI]: 21,15–48,08) et 30,77 (EI: 21,15–46,15) pour la première et la deuxième administration, respectivement. La fiabilité test-retest (CCI: 0,73 ; IC95%: 0,63–0,81) et la cohérence interne (alpha de Cronbach: 0,80) étaient bonnes. Une corrélation positive modérée a été observée entre le score au MTBQ-F et le nombre de conditions autorapportées (rho: 0,28). Cet instrument valide permettrait d’identifier les patients expérimentant un fardeau de traitement élevé et d’évaluer l’impact des interventions réalisées chez cette population.Abstract:Reliable treatment burden measures are needed given the aging population and the associated increase in multimorbidity and polypharmacy. Treatment burden is defined as the effort to care for one’s health and the resulting impact on one’s daily life. This study aimed to translate the Multimorbidity Treatment Burden Questionnaire (MTBQ) for French-Canadians and assess its reliability and validity. The MTBQ was translated and tested with cognitive debriefing interviews, and the French version (MTBQ-F) was then administered 2 times among 105 participants. Reliability and validity were examined using the intra-class correlation coefficient (ICC), Cronbach’s alpha, and Spearman’s correlations. The median global MTBQ-F scores were 32.69 (interquartile range [IQR]: 21.15–48.08) and 30.77 (IQR: 21.15–46.15) for the first and second administrations, respectively. Test-retest (ICC: 0.73; 95% CI: 0.63–0.81) and internal consistency reliability (Cronbach’s alpha: 0.80) were good. There was a moderate positive correlation between the MTBQ-F score and the number of self-reported conditions (rho: 0.28). This valid instrument could identify patients experiencing a high treatment burden and assess the impact of interventions among them.

AbstractReliable treatment burden measures are needed given the aging population and the associated increase in multimorbidity and polypharmacy. Treatment burden is defined as the effort to care for one’s health and the resulting impact on one’s daily life. This study aimed to translate the Multimorbidity Treatment Burden Questionnaire (MTBQ) for French-Canadians and assess its reliability and validity. The MTBQ was translated and tested with cognitive debriefing interviews, and the French version (MTBQ-F) was then administered 2 times among 105 participants. Reliability and validity were examined using the intra-class correlation coefficient (ICC), Cronbach’s alpha, and Spearman’s correlations. The median global MTBQ-F scores were 32.69 (interquartile range [IQR]: 21.15-48.08) and 30.77 (IQR: 21.15-46.15) for the first and second administrations, respectively. Test-retest (ICC: 0.73; 95% CI: 0.63-0.81) and internal consistency reliability (Cronbach’s alpha: 0.80) were good. There was a moderate positive correlation between the MTBQ-F score and the number of self-reported conditions (rho: 0.28). This valid instrument could identify patients experiencing a high treatment burden and assess the impact of interventions among them.